The Institute for Clinical and Economic Review on Tuesday announced plans to evaluate the comparative clinical effectiveness and value of Novartis’ AVXS-101 and Biogen’s nusinersen for treating spinal muscular atrophy (SMA).
According to a press release, the report will be reviewed during a March 2019 meeting of the New England Comparative Effectiveness Public Advisory Council.
Biogen’s nusinersen was OK’d in 2016 to treat SMA in children and adults. Researchers are conducting studies on AVXS-101, a gene therapy which is being studied for treatment of SMA in infants.
“The formal scope of ICER’s review — including the drugs reviewed, special subpopulations of interest, and basic approach to economic modeling — will be finalized with the benefit of input from all stakeholders, including clinical experts and patients,” ICER states in a press release.
An open input period began today (July 31) and will remain open to all stakeholders until 5 p.m. EST Aug. 17.
For more information on ICER, visit its website by clicking here.